Q2
BIAF — Q2 2026 Financial Report Analysis
CyPath Lung tests tripled to 622 and revenue rose 19% to $1.51M, but the operating loss widened 33% to $3.33M, cash was down to $1.0M by early August, and growth is being funded by heavy share dilution and a second reverse split.